- Dec 12, 2000
- 24,817
- 9,027
- 136
Taxpayers Paid Millions to Design a Low-Cost Ventilator for a Pandemic. Instead, the Company Is Selling Versions of It Overseas.
As coronavirus sweeps the globe, there is not a single Trilogy Evo Universal ventilator — developed with government funds — in the U.S. stockpile. Meanwhile, Royal Philips N.V. has sold higher-priced versions to clients around the world.
www.propublica.org
Taxpayers Paid Millions to Design a Low-Cost Ventilator for a Pandemic. Instead, the Company Is Selling Versions of It Overseas.
As coronavirus sweeps the globe, there is not a single Trilogy Evo Universal ventilator — developed with government funds — in the U.S. stockpile. Meanwhile, Royal Philips N.V. has sold higher-priced versions to clients around the world.
Cliffs:
- 2014: Obama's HHS realizes US hospitals will face a critical shortage of ventilators in a pandemic. HHS signs $13.8M contract with Respironics (Philips' subsidiary) to design and develop a low-cost, American-made portable ventilator for US stockpile.
- 2019: Trump's FDA clears the final design and HHS orders 10,000 units at $3,280 each. So far, so good...except:
- After receiving FDA approval, Philips starts manufacturing and selling a higher-priced $12,500 SKU of the ventilator for overseas customers.
- 2020: Covid-19 sweeps the globe. Not a single respirator has been delivered to the stockpile. Why? Turns out the order HHS placed late in 2019 gave Philips 1 year to produce Unit 1 and 3 years to complete delivery. Doh. Obama's HHS in 2014 insisted that potential partners would need to ramp up production quickly in the event a pandemic is declared. That language didn't make it in the final order contract.
- HHS gets Philips to agree to an amendment in March, but they still don't guarantee production will start immediately.
- Trump touts the Defense Production Act and threatens to compel GM into ventilator production. Says nothing about Philips/Respironics.
- Philips negotiates with Jared Kushner to build 43,000 of the more expensive ventilators for the stockpile on taxpayers' dime.
In short, America pays a company to design and develop a ventilator; said company commercializes a higher-priced version and never builds the government version; government then renegotiates for the higher-priced version amid a pandemic. Profit!
These public/private partnerships are really working out, aren't they?